Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Greg was also central to the planning, design, and construction of this facility
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Subscribe To Our Newsletter & Stay Updated
